Events
ASLAN Pharmaceuticals announced the presentation of new data from a phase 1b open-label, dose escalation study of varlitinib in combination with modified irinotecan and infusional 5-fluorouracil chemotherapy to determine the safety, tolerability and maximum tolerated dose in advanced solid tumours.
Novadip Biosciences will present a case study highlighting the results of a scaffold-free, 3-dimensional autologous cell therapy for the treatment of critical size bone reconstruction at the European Orthopaedic Research Society 2019 conference in Maastricht, The Netherlands.
Advanced composite alternative to steel tubing to be showcased in Hall 8a, Stand H03
StableView Asset Management is a full-service asset and wealth management firm that caters to individual clients and institutional investors.
Global Blood Therapeutics, Inc., announced that it will host an Analyst & Investor Day to provide an update to the investment community on the company’s development and commercial strategy for voxelotor for sickle cell disease.
Imugene Limited, a clinical stage immuno-oncology company, announced comprehensive clinical data results from the Phase Ib clinical study of its HER-Vaxx anti-cancer vaccine were presented at the European Society of Medical Oncology in Barcelona, Spain held from 27 September to 1 October 2019.
Imugene Limited announced two presentations by medical investigators at the European Society of Medical Oncology in Barcelona Spain showed combining its HER2 vaccines with PD1 vaccines reduced cancer growth in a number of standard preclinical models.
A multicenter, international, single-arm, Phase II trial of lurbinectedin in progressive Malignant Pleural Mesothelioma (MPM) has been presented at ESMO.
Evgen Pharma plc announces that the clinical data from the completed open-label Phase II STEM trial was presented in poster format yesterday at the 2019 European Society of Medical Oncology Congress in Barcelona.
NOXXON Pharma N.V. announced the latest clinical results from the Phase 1/2 study of NOX-A12 in combination with Keytruda® in patients with microsatellite-stable, metastatic pancreatic and colorectal cancer in a poster presentation at the European Society for Medical Oncology Congress in Barcelona, Spain.
PRESS RELEASES